• In April 2026, CTS Corporation reported first-quarter 2026 results showing higher sales of US$139.23 million and net income of US$17.2 million year on year, completed a US$18.28 million buyback of 405,242 shares announced in November 2025, and narrowed its 2026 sales guidance range to US$560 million–US$580 million.
• Management also highlighted plans to continue pursuing acquisitions to enhance diversification and earnings quality, signaling an ongoing focus on capital deployment beyond organic growth.
• Next, we’ll examine how the raised 2026 sales guidance and ongoing acquisition plans feed into CTS Corporation’s existing investment narrative.

Find 49 companies with promising cash flow potential yet trading below their fair value.

CTS Investment Narrative Recap

To own CTS, you need to believe the company can keep shifting from legacy transportation exposure toward more diversified, higher quality earnings while managing trade and geopolitical pressures. The latest results, higher sales guidance, and confirmed appetite for acquisitions support that narrative in the near term, while ongoing softness risks in transportation and certain medical lines remain the key watchpoints. The Q1 update does not materially change the biggest risk, which is end market volatility in CTS’s core segments.

The completion of the US$18.28 million buyback, alongside narrowed 2026 sales guidance of US$560 million to US$580 million, is the most relevant recent update here. Together, they frame how management is currently balancing reinvestment and capital returns while it continues to look for acquisitions that could reinforce the diversification catalyst investors are focused on.

Yet even with better guidance, investors should be aware that exposure to transportation volumes and China-related tariff risk could still...

CTS’ narrative projects $639.6 million revenue and $89.0 million earnings by 2029.

Uncover how CTS' forecasts yield a $58.00 fair value, a 6% downside to its current price.

Exploring Other Perspectives

Two fair value estimates from the Simply Wall St Community cluster between US$58.00 and about US$62.12 per share, underscoring how opinions can differ even in a narrow range. You should weigh those views against CTS’s reliance on transportation and medical demand, where any prolonged softness could affect how the business performs over time.

Explore 2 other fair value estimates on CTS - why the stock might be worth as much as $62.12!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your CTS research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free CTS research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CTS' overall financial health at a glance.

Contemplating Other Strategies?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Rare earth metals are the new gold rush. Find out which 33 stocks are leading the charge.
• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.